JP4098985B2 - テトラヒドロピペリンならびにその類似体および誘導体を用いて栄養素および薬剤調製物の生体利用能を高める方法 - Google Patents

テトラヒドロピペリンならびにその類似体および誘導体を用いて栄養素および薬剤調製物の生体利用能を高める方法 Download PDF

Info

Publication number
JP4098985B2
JP4098985B2 JP2001585813A JP2001585813A JP4098985B2 JP 4098985 B2 JP4098985 B2 JP 4098985B2 JP 2001585813 A JP2001585813 A JP 2001585813A JP 2001585813 A JP2001585813 A JP 2001585813A JP 4098985 B2 JP4098985 B2 JP 4098985B2
Authority
JP
Japan
Prior art keywords
tetrahydropiperine
piperine
test
skin
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001585813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003534295A (ja
JP2003534295A5 (https=
Inventor
ムハムド マジェード
ウラジミール バドマエフ
クマー ラジンダー バミイ
サバラクシミ プラカシ
サンカラン ナタラヤン
Original Assignee
サビンサ コーポレーション
サミ ラブズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サビンサ コーポレーション, サミ ラブズ リミテッド filed Critical サビンサ コーポレーション
Publication of JP2003534295A publication Critical patent/JP2003534295A/ja
Publication of JP2003534295A5 publication Critical patent/JP2003534295A5/ja
Application granted granted Critical
Publication of JP4098985B2 publication Critical patent/JP4098985B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Fodder In General (AREA)
JP2001585813A 2000-05-19 2001-05-21 テトラヒドロピペリンならびにその類似体および誘導体を用いて栄養素および薬剤調製物の生体利用能を高める方法 Expired - Lifetime JP4098985B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20524500P 2000-05-19 2000-05-19
US60/205,245 2000-05-19
US27797901P 2001-03-23 2001-03-23
US60/277,979 2001-03-23
PCT/US2001/016070 WO2001089571A2 (en) 2000-05-19 2001-05-21 Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives

Publications (3)

Publication Number Publication Date
JP2003534295A JP2003534295A (ja) 2003-11-18
JP2003534295A5 JP2003534295A5 (https=) 2007-04-19
JP4098985B2 true JP4098985B2 (ja) 2008-06-11

Family

ID=26900240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001585813A Expired - Lifetime JP4098985B2 (ja) 2000-05-19 2001-05-21 テトラヒドロピペリンならびにその類似体および誘導体を用いて栄養素および薬剤調製物の生体利用能を高める方法

Country Status (6)

Country Link
US (1) US6849645B2 (https=)
JP (1) JP4098985B2 (https=)
AU (1) AU2001278849A1 (https=)
DE (2) DE10196213T1 (https=)
GB (1) GB2380675B (https=)
WO (1) WO2001089571A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529123A (ja) * 2002-04-24 2005-09-29 リサーチ　ディベロップメント　ファンデーション 核転写調節因子ＮＦ−κＢ抑制剤と抗腫瘍薬の相乗効果
CA2489947A1 (en) * 2002-06-24 2003-12-31 Research Development Foundation Treatment of human multiple myeloma by curcumin
WO2004067018A1 (en) * 2003-01-30 2004-08-12 Council Of Scientific And Industrial Research Bioavailability enhancing activity of carum carvi extracts and fractions thereof
US7462646B2 (en) 2003-08-26 2008-12-09 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
US20050163873A1 (en) * 2004-01-14 2005-07-28 Robert Ritch Methods and formulations for treating glaucoma
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20060130675A1 (en) * 2004-11-30 2006-06-22 Crawford David S Transdermal nutritional supplement delivery patch
US8372040B2 (en) 2005-05-24 2013-02-12 Chrono Therapeutics, Inc. Portable drug delivery device including a detachable and replaceable administration or dosing element
US20070237735A1 (en) * 2006-03-31 2007-10-11 Laboratoires Dermo-Cosmetik Inc. Anti-aging composition, kit and method of use
US20080138417A1 (en) * 2006-11-22 2008-06-12 Charles Grigsby Topical Composition And Method Of Forming
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
WO2017020125A1 (en) * 2015-07-31 2017-02-09 Delivra Inc. Transdermal formulations for delivery of capsaicinoids
KR102655937B1 (ko) * 2016-09-27 2024-04-11 (주)아모레퍼시픽 코스모페린을 포함하는 항스트레스 조성물
WO2018069938A1 (en) * 2016-10-14 2018-04-19 Cipla Limited Pharmaceutical compositions comprising rifaximin
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
WO2019058386A1 (en) * 2017-09-19 2019-03-28 Cipla Limited COMPOSITIONS COMPRISING IBRUTINIB AND AN ALKALOID HAVING IMPROVED BIOAVAILABILITY
EP3801732A4 (en) 2018-05-29 2022-04-27 Morningside Venture Investments Limited METHODS AND SYSTEMS FOR DRUG DELIVERY
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
US20200179362A1 (en) * 2018-12-05 2020-06-11 James E. Beecham Dietary supplement comprising glucuronidation inhibition assist for healthful daily synergy of anti-inflammation, cellular anti-oxidant boost, cellular protein clean-up boost
JP7163261B2 (ja) * 2019-09-27 2022-10-31 富士フイルム株式会社 水中油型乳化組成物、及び皮膚外用剤
CN115670998A (zh) * 2022-11-18 2023-02-03 广州澳莱娜生物科技有限公司 一种祛痘控油亮肤组合物及其制备方法
CN115813822B (zh) * 2022-12-16 2024-06-25 厦门海尼新创生物科技有限公司 一种高效祛痘组合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984001264A1 (fr) * 1982-09-30 1984-04-12 Dainippon Jochugiku Kk Appareil de volatilisation thermique d'un agent medicinal
AU4382693A (en) * 1992-05-21 1993-12-13 Jeff J. Staggs Therapeutic uses of pungent botanicals and their related compounds
CA2098889A1 (en) * 1992-07-06 1994-01-07 Takashi Chinuki Slow-releasing medicated resin moldings and process for producing the same
EP0650728B1 (en) * 1993-10-29 2002-02-27 Council of Scientific and Industrial Research Pharmaceutical compositions containing piperine and an antituberculosis or antileprosydrug
IN176897B (https=) * 1993-10-29 1996-09-28 Cadila Lab Ltd
JP2946452B2 (ja) * 1994-11-04 1999-09-06 カディラ ラボラトリーズ リミテッド ピペリンを含む組成物
US5744161A (en) * 1995-02-24 1998-04-28 Sabinsa Corporation Use of piperine as a bioavailability enhancer
EP0935964A1 (en) * 1998-02-12 1999-08-18 Panacea Biotec Limited Pharmaceutical compositions containing NSAIDs and piperine
GB9815177D0 (en) * 1998-07-13 1998-09-09 King S College London Treatment of skin disorders

Also Published As

Publication number Publication date
US6849645B2 (en) 2005-02-01
WO2001089571A2 (en) 2001-11-29
DE10196213T1 (de) 2003-04-30
JP2003534295A (ja) 2003-11-18
DE10196213B4 (de) 2020-12-17
GB0229561D0 (en) 2003-01-22
WO2001089571A3 (en) 2002-03-07
GB2380675B (en) 2004-11-03
GB2380675A (en) 2003-04-16
AU2001278849A1 (en) 2001-12-03
US20020058695A1 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
JP4098985B2 (ja) テトラヒドロピペリンならびにその類似体および誘導体を用いて栄養素および薬剤調製物の生体利用能を高める方法
JP7374951B2 (ja) 安定なカンナビノイド製剤
CN101790370B (zh) 一种新的双氯芬酸非水局部用溶液及其制备方法
CN115038430B (zh) 自微乳化的多种可递送物的系统
KR20130129953A (ko) 난용성 화합물의 용해도를 증가시키는 방법과 이와 같은 화합물의 제형을 제조하는 방법 및 사용하는 방법
KR20170008311A (ko) 안정한 카나비노이드 제형
WO1998008966A1 (en) Loxoprofen-containing preparation for external use
JP2004515453A (ja) 癌を化学療法および放射線療法に付する間に細胞を保護するための組成物および方法
ES2886673T3 (es) Un proceso para la preparación de curcumina blanca biodisponible, una mezcla única de curcuminoides hidrogenados
US20160256513A1 (en) Synergized turmeric
KR20140008364A (ko) 염증후 색소과다침착의 치료를 위한 바쿠치올 조성물
CA2994331C (en) Transdermal formulations for delivery of capsaicinoids
Marquele-Oliveira et al. Physicochemical characterization by AFM, FT-IR and DSC and biological assays of a promising antileishmania delivery system loaded with a natural Brazilian product
JP7758770B2 (ja) 基底細胞がんおよび神経膠芽腫を治療する方法
US10369170B1 (en) Methods of treating basal cell carcinoma and glioblastoma
Sarangamath et al. Invasomes: A vesicular carrier for transdermal delivery
Tufail et al. Formulation and characterization of herbosome: A review
JP5897299B2 (ja) ローション剤
Mazzacuva et al. Curcumin and Neglected Infectious Diseases
CN115209890B (zh) 抑制促炎基因表达的紫草素、芳基萘木酚素以及包含它们的药物组合物
Dalal et al. Phytonanomedicines as Topical Alternatives for the Treatment of Skin Cancer
FR3004651A1 (fr) Composition pharmaceutique ou dietetique ayant pour objet l augmentation du passage des xenobiotiques des medicaments et des nutriments au travers des barrieres biologiques
US20240207289A1 (en) Method to identify and alleviate the symptoms of parkinsonism/parkinson’s disease
Sarker et al. Formulation and Delivery of Mitragynine: A Mini Review
CA3175700A1 (en) Lipid crystalline compositions with enhanced stability for topical delivery of active agent combinations

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20061117

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20061117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070228

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20070228

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20070329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080314

R150 Certificate of patent or registration of utility model

Ref document number: 4098985

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110321

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110321

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130321

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140321

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term